scholarly article | Q13442814 |
P50 | author | Kathleen Neuzil | Q76169016 |
Frederick G Hayden | Q87843428 | ||
Geoffrey J Gorse | Q89260570 | ||
Stefan Gravenstein | Q90366549 | ||
Maria Zambon | Q91506671 | ||
Janet E McElhaney | Q92876176 | ||
Eric A F Simões | Q109845655 | ||
P2093 | author name string | Ann R Falsey | |
Robert Edelman | |||
Edward E Walsh | |||
Peter F Wright | |||
Eddy Yau | |||
Jose Capellan | |||
Kristen L Nichol | |||
Valérie M-P Sales | |||
P2860 | cites work | Mortality associated with influenza and respiratory syncytial virus in the United States | Q29615578 |
Influenza-associated hospitalizations in the United States | Q29619463 | ||
Respiratory syncytial virus and parainfluenza virus | Q33952428 | ||
Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group | Q34094440 | ||
Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines | Q34285502 | ||
Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group | Q34358628 | ||
Adjuvants for human vaccines--current status, problems and future prospects | Q34373525 | ||
Respiratory syncytial virus infection in elderly and high-risk adults | Q34414401 | ||
The future of respiratory syncytial virus vaccine development | Q35632372 | ||
Comparison of quantitative reverse transcription-PCR to viral culture for assessment of respiratory syncytial virus shedding | Q35922051 | ||
Respiratory syncytial virus infections in previously healthy working adults | Q40597674 | ||
Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registry | Q43821315 | ||
Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults | Q43979004 | ||
Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults | Q44621708 | ||
Serum antibody decay in adults following natural respiratory syncytial virus infection | Q45411871 | ||
Experimental infection of humans with A2 respiratory syncytial virus | Q45571445 | ||
Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes | Q45610521 | ||
Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults | Q45623141 | ||
Age related differences in humoral immune response to respiratory syncytial virus infection in adults | Q45644291 | ||
Risk factors for severe respiratory syncytial virus infection in elderly persons | Q45699277 | ||
Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease | Q45732316 | ||
Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study | Q45734830 | ||
Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly | Q45760956 | ||
Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. | Q45765792 | ||
Respiratory syncytial virus or influenza? | Q45783418 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | influenza vaccine | Q383260 |
vaccine | Q134808 | ||
P304 | page(s) | 1317-1326 | |
P577 | publication date | 2008-11-01 | |
P1433 | published in | Journal of Infectious Diseases | Q4051141 |
P1476 | title | Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals | |
P478 | volume | 198 |
Q45382330 | A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age. |
Q92310272 | Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations |
Q36606731 | Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein |
Q45326384 | An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults |
Q36500189 | An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice |
Q35185596 | Central role of dendritic cells in shaping the adaptive immune response during respiratory syncytial virus infection |
Q35077892 | Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice |
Q37197103 | Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology |
Q90668023 | Development and verification of real-time PCR assay for identification of viral agents causing acute respiratory infections in human beings |
Q35986962 | Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial Virus |
Q26782411 | Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genes |
Q40134310 | Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses |
Q41553098 | Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques |
Q33601830 | Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells |
Q37371036 | Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations. |
Q33555911 | Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults |
Q90681995 | Impact of Respiratory Syncytial Virus Infection on the Host Cell: Implications for Antiviral Strategies |
Q24188037 | Influenza vaccines for preventing cardiovascular disease |
Q54338791 | Inhibitory effect of potassium alum on smooth muscle contraction of rabbit and its mechanism. |
Q45374783 | Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation |
Q90015591 | Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection |
Q33837530 | Mucosal vaccines against respiratory syncytial virus |
Q33489541 | NGF is an essential survival factor for bronchial epithelial cells during respiratory syncytial virus infection |
Q39318498 | Passive and active immunization against respiratory syncytial virus for the young and old. |
Q33776507 | Pharmacologic advances in the treatment and prevention of respiratory syncytial virus |
Q37461377 | Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response |
Q56894869 | Progress in respiratory virus vaccine development |
Q35566601 | Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years |
Q37991125 | Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients |
Q34262180 | Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice |
Q38617302 | Recent advances in the development of subunit-based RSV vaccines. |
Q39118423 | Respiratory Syncytial Virus Infection: An Illness for All Ages |
Q41349182 | Respiratory syncytial virus infection in older adults: an under-recognized problem |
Q56893551 | Respiratory syncytial virus vaccine development |
Q84854616 | Respiratory syncytial virus vaccine development |
Q59354124 | Respiratory syncytial virus-associated illness in adults with advanced chronic obstructive pulmonary disease and/or congestive heart failure |
Q37572640 | Strategic priorities for respiratory syncytial virus (RSV) vaccine development |
Q37328584 | Targeting RSV with vaccines and small molecule drugs |
Q38630273 | The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review |
Q40933366 | The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis. |
Q34222406 | The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents |
Q50120750 | The role of vaccines in preventing bacterial antimicrobial resistance |
Q38140040 | Translational sciences approach to RSV vaccine development |
Q38660842 | Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis. |
Q91449694 | Updates on immunologic correlates of vaccine-induced protection |
Q37514757 | Vaccination against RSV: is maternal vaccination a good alternative to other approaches? |
Q45326393 | Vaccine Prevention of Respiratory Syncytial Virus in Older Adults: The Work Continues |
Q39318444 | Vaccine development for respiratory syncytial virus |
Q24201977 | Vaccines for the common cold |
Q38682527 | Vaccines for the common cold |
Q64098587 | Will Attention by Vaccine Developers to the Host's Nuclear Hormone Levels and Immunocompetence Improve Vaccine Success? |
Search more.